Critics hope new cabinet will put a stop to drug-price regulation changes
OTTAWA — Critics of a major drug-price overhaul hope a fresh federal cabinet will put a temporary stop to the new regulations set to take effect in January.
The Patented Medicine Prices Review Board is set to change the way it sets a price cap on medicines in Canada in an effort to lower excessively expensive drug costs.
Several groups, including a coalition of eight Canadian life-sciences organizations, have written to government ministers to ask them to put off the changes pending more consultation, input from the new federal cabinet, and the resolution of several legal challenges.
The overhaul has drawn the disapproval of patient groups and drug manufacturers, as well as some pharmacists, doctors, academics and even provincial governments.